Skip to main content
Clinical Trials/NCT05201300
NCT05201300
Completed
Not Applicable

Comparison of Remimazolam and Propofol Anesthesia on Hemodynamic and Recovery Profile in Elderly Patients

Ajou University School of Medicine1 site in 1 country69 target enrollmentFebruary 2, 2022

Overview

Phase
Not Applicable
Intervention
Remimazolam Besylate 6 mg/kg/hr
Conditions
Hemodynamics
Sponsor
Ajou University School of Medicine
Enrollment
69
Locations
1
Primary Endpoint
difference in the decreased mean arterial pressure
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Remimazolam is a recently developed ultra-short agonist acting at the benzodiazepine binding site of the gamma-aminobutyric acid (GABA)A receptor. Remimazolam has a combination of the hemodynamic stability of benzodiazepines and the advantages of propofol, such as rapid onset, short duration of action, and improved controllability.

A recent study showed that the efficacy of two induction doses of remimazolam (6 and 12 mg/kg/h) as a sedative for general anesthesia was not inferior to propofol (2.0-2.5 mg/kg), and hemodynamically more stable. On the other hand, a study on the emergence time and quality between propofol and remimazolam showed inconsistent results.

The purpose of this study is to compare remimazolam to propofol on the intraoperative hemodynamic changes and recovery profiles, when used in combination with remifentanil in elderly patients undergoing general anesthesia.

Registry
clinicaltrials.gov
Start Date
February 2, 2022
End Date
January 18, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Ajou University School of Medicine
Responsible Party
Principal Investigator
Principal Investigator

Jong Yeop Kim

Professor

Ajou University School of Medicine

Eligibility Criteria

Inclusion Criteria

  • ASA I, II patients over 65 years old undergoing general anesthesia

Exclusion Criteria

  • cardiac surgery
  • neurosurgery
  • liver surgery
  • uncontrolled hypertension
  • bronchial asthma
  • body mass index ≥ 30 kg/m2
  • severe heart, liver, kidney disease

Arms & Interventions

Remimazolam 6

Remimazolam starts at 6 mg/kg/hr until loss of consciousness

Intervention: Remimazolam Besylate 6 mg/kg/hr

Remimazolam 12

Remimazolam starts at 12 mg/kg/hr until loss of consciousness

Intervention: Remimazolam Besylate 12 mg/kg/hr

Propofol

Propofol starts at a target controlled infusion 4 µg/ml until loss of consciousness.

Intervention: Propofol

Outcomes

Primary Outcomes

difference in the decreased mean arterial pressure

Time Frame: from the start of anesthetics (propofol or remimazolam) injection to the 5 minutes after extubation

difference between baseline mean arterial pressure and lowest mean arterial pressure

Study Sites (1)

Loading locations...

Similar Trials